$EGRX
EAGLE PHARMACEUTICALS, INC.

2021 Q2 Form 10-Q Financial Statement

#000082787121000022 Filed on August 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2 2020 Q1
Revenue $48.12M $41.94M $46.02M
YoY Change 14.75% -26.04% -7.56%
Cost Of Revenue $7.907M $10.31M $4.765M
YoY Change -23.33% -43.26% -50.13%
Gross Profit $40.22M $31.63M $41.26M
YoY Change 27.17% -10.71% 12.46%
Gross Profit Margin 83.57% 75.41% 89.65%
Selling, General & Admin $16.64M $17.96M $24.76M
YoY Change -7.37% 4.24% 36.46%
% of Gross Profit 41.37% 56.79% 60.0%
Research & Development $9.911M $7.135M $9.427M
YoY Change 38.91% -20.34% 47.87%
% of Gross Profit 24.64% 22.56% 22.85%
Depreciation & Amortization $188.0K $209.0K $251.0K
YoY Change -10.05% -13.28% 3.72%
% of Gross Profit 0.47% 0.66% 0.61%
Operating Expenses $26.55M $25.09M $34.18M
YoY Change 5.79% -47.14% -9.13%
Operating Profit $10.82M $3.709M $4.035M
YoY Change 191.72% -59.83% -66.84%
Interest Expense $422.0K $786.0K $889.0K
YoY Change -46.31% 18.2% 29.59%
% of Operating Profit 3.9% 21.19% 22.03%
Other Income/Expense, Net -$5.272M $1.664M -$7.043M
YoY Change -416.83% -6042.86% 3568.23%
Pretax Income $5.548M $5.373M -$3.008M
YoY Change 3.26% -41.63% -125.11%
Income Tax $1.936M $5.629M -$137.0K
% Of Pretax Income 34.9% 104.76%
Net Earnings $3.612M -$256.0K -$2.871M
YoY Change -1510.94% -103.81% -132.0%
Net Earnings / Revenue 7.51% -0.61% -6.24%
Basic Earnings Per Share $0.28 -$0.02 -$0.21
Diluted Earnings Per Share $0.27 -$0.02 -$0.21
COMMON SHARES
Basic Shares Outstanding 13.11M shares 13.66M shares 13.67M shares
Diluted Shares Outstanding 13.26M shares 13.66M shares 13.67M shares

Balance Sheet

Concept 2021 Q2 2020 Q2 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $108.7M $108.2M $202.0M
YoY Change 0.48% 0.09% 97.85%
Cash & Equivalents $108.7M $108.2M $202.0M
Short-Term Investments
Other Short-Term Assets $4.458M $1.250M $691.0K
YoY Change 256.64% 369.92% 72.32%
Inventory $8.294M $7.891M $8.434M
Prepaid Expenses
Receivables $52.66M $46.78M $54.49M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $175.5M $168.4M $275.6M
YoY Change 4.2% -9.28% 51.22%
LONG-TERM ASSETS
Property, Plant & Equipment $1.967M $2.118M $2.423M
YoY Change -7.13% -6.2% 3.86%
Goodwill $39.74M $39.74M $39.74M
YoY Change 0.0% 0.0% 0.0%
Intangibles $11.51M $14.25M $14.92M
YoY Change -19.26% -15.4% -14.63%
Long-Term Investments
YoY Change
Other Assets $21.46M $17.58M $15.53M
YoY Change 22.1% 453.12% 335.62%
Total Long-Term Assets $88.74M $88.27M $86.37M
YoY Change 0.53% 16.19% 11.85%
TOTAL ASSETS
Total Short-Term Assets $175.5M $168.4M $275.6M
Total Long-Term Assets $88.74M $88.27M $86.37M
Total Assets $264.2M $256.7M $361.9M
YoY Change 2.93% -1.88% 39.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.14M $13.71M $9.756M
YoY Change -18.76% -20.74% -41.88%
Accrued Expenses $25.53M $19.78M $20.12M
YoY Change 29.07% -32.84% -10.31%
Deferred Revenue $4.339M $5.774M $6.019M
YoY Change -24.85% -50.65%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $8.000M $7.000M $116.0M
YoY Change 14.29% 40.0% 2220.0%
Total Short-Term Liabilities $44.66M $40.49M $145.9M
YoY Change 10.32% -21.76% 229.88%
LONG-TERM LIABILITIES
Long-Term Debt $21.37M $28.90M $30.78M
YoY Change -26.05% -19.37% -16.81%
Other Long-Term Liabilities $3.360M $3.361M $3.454M
YoY Change -0.03% 115.45% 20.35%
Total Long-Term Liabilities $24.73M $32.26M $34.24M
YoY Change -23.34% -13.75% -14.13%
TOTAL LIABILITIES
Total Short-Term Liabilities $44.66M $40.49M $145.9M
Total Long-Term Liabilities $24.73M $32.26M $34.24M
Total Liabilities $69.40M $72.75M $180.1M
YoY Change -4.61% -18.4% 114.19%
SHAREHOLDERS EQUITY
Retained Earnings $87.68M $69.37M $69.63M
YoY Change 26.39% -6.11% 3.68%
Common Stock $17.00K $17.00K $17.00K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $208.2M $176.9M $172.9M
YoY Change 17.72% 4.71% 12.32%
Treasury Stock Shares 3.783M shares 3.018M shares 2.933M shares
Shareholders Equity $194.8M $184.0M $181.8M
YoY Change
Total Liabilities & Shareholders Equity $264.2M $256.7M $361.9M
YoY Change 2.93% -1.88% 39.5%

Cashflow Statement

Concept 2021 Q2 2020 Q2 2020 Q1
OPERATING ACTIVITIES
Net Income $3.612M -$256.0K -$2.871M
YoY Change -1510.94% -103.81% -132.0%
Depreciation, Depletion And Amortization $188.0K $209.0K $251.0K
YoY Change -10.05% -13.28% 3.72%
Cash From Operating Activities $8.591M $20.95M $3.158M
YoY Change -58.99% -6.43% -87.94%
INVESTING ACTIVITIES
Capital Expenditures $111.0K $90.00K $472.0K
YoY Change 23.33% -156.25% 166.67%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 -$17.50M
YoY Change
Cash From Investing Activities $111.0K $90.00K -$17.97M
YoY Change 23.33% -156.25% 10053.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $999.0K
YoY Change
Debt Paid & Issued, Net $1.000M
YoY Change -60.0%
Cash From Financing Activities -5.220M -114.9M $107.1M
YoY Change -95.46% 607.7% -4130.69%
NET CHANGE
Cash From Operating Activities 8.591M 20.95M $3.158M
Cash From Investing Activities 111.0K 90.00K -$17.97M
Cash From Financing Activities -5.220M -114.9M $107.1M
Net Change In Cash 3.482M -93.82M $92.24M
YoY Change -103.71% -1663.67% 295.07%
FREE CASH FLOW
Cash From Operating Activities $8.591M $20.95M $3.158M
Capital Expenditures $111.0K $90.00K $472.0K
Free Cash Flow $8.480M $20.86M $2.686M
YoY Change -59.35% -7.49% -89.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000827871
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2021Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2021Q2 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36306
dei Entity Registrant Name
EntityRegistrantName
Eagle Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8179278
dei Entity Address Address Line1
EntityAddressAddressLine1
50 Tice Boulevard
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 315
dei Entity Address City Or Town
EntityAddressCityOrTown
Woodcliff Lake
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07677
dei City Area Code
CityAreaCode
(201)
dei Local Phone Number
LocalPhoneNumber
326-5300
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
EGRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2021Q2 us-gaap Inventory Net
InventoryNet
8294000 USD
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13097113 shares
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
108717000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103155000 USD
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
52659000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
50678000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
8075000 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5834000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4157000 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
175504000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
166065000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1967000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2077000 USD
CY2021Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
11505000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12917000 USD
CY2021Q2 us-gaap Goodwill
Goodwill
39743000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
39743000 USD
CY2021Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
14061000 USD
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
15180000 USD
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
21462000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
17208000 USD
CY2021Q2 us-gaap Assets
Assets
264242000 USD
CY2020Q4 us-gaap Assets
Assets
253190000 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
11136000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6268000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25528000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23817000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 USD
CY2021Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
8000000 USD
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
8000000 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
44664000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
38085000 USD
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3360000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3959000 USD
CY2021Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
21371000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
25135000 USD
CY2021Q2 us-gaap Liabilities
Liabilities
69395000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
67179000 USD
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1500000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1500000 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16879974 shares
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16739203 shares
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
17000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
17000 USD
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
316249000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
305403000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-904000 USD
us-gaap Costs And Expenses
CostsAndExpenses
82326000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
87680000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
84489000 USD
CY2021Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
3782861 shares
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
3682176 shares
CY2021Q2 us-gaap Treasury Stock Value
TreasuryStockValue
208195000 USD
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
203898000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
194847000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
186011000 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
264242000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
253190000 USD
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
48124000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41938000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
89373000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
87958000 USD
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7907000 USD
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
10313000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
16349000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
15078000 USD
CY2021Q2 us-gaap Royalty Expense
RoyaltyExpense
2850000 USD
CY2020Q2 us-gaap Royalty Expense
RoyaltyExpense
2822000 USD
us-gaap Royalty Expense
RoyaltyExpense
5263000 USD
us-gaap Royalty Expense
RoyaltyExpense
5860000 USD
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9911000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7135000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24199000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16562000 USD
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16636000 USD
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17959000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36515000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
42714000 USD
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
37304000 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
38229000 USD
us-gaap Costs And Expenses
CostsAndExpenses
80214000 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
10820000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
3709000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
7047000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
7744000 USD
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
163000 USD
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
150000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
198000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
496000 USD
CY2021Q2 us-gaap Interest Expense
InterestExpense
422000 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
786000 USD
us-gaap Interest Expense
InterestExpense
844000 USD
us-gaap Interest Expense
InterestExpense
1675000 USD
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5013000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2300000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
487000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4200000 USD
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5272000 USD
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1664000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-159000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5379000 USD
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5548000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5373000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6888000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2365000 USD
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1936000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5629000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3697000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5492000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
3612000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-256000 USD
us-gaap Net Income Loss
NetIncomeLoss
3191000 USD
us-gaap Net Income Loss
NetIncomeLoss
-3127000 USD
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.27
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13108998 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13664951 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13116370 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13666279 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13262164 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13664951 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13293920 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13666279 shares
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
3612000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-256000 USD
us-gaap Net Income Loss
NetIncomeLoss
3191000 USD
us-gaap Net Income Loss
NetIncomeLoss
-3127000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-904000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-904000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-904000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-904000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2708000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-256000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2287000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3127000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
191078000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4281000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-355000 USD
CY2021Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
2865000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-904000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
3612000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
194847000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
186011000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10789000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1608000 USD
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-1551000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
4297000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-904000 USD
us-gaap Net Income Loss
NetIncomeLoss
3191000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
194847000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
181830000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6241000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
183000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1223000 USD
CY2020Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
34000 USD
CY2020Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
4000000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-256000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
183964000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
179174000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13713000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
513000 USD
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1310000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
4999000 USD
us-gaap Net Income Loss
NetIncomeLoss
-3127000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
183964000 USD
us-gaap Net Income Loss
NetIncomeLoss
3191000 USD
us-gaap Net Income Loss
NetIncomeLoss
-3127000 USD
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
1119000 USD
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-916000 USD
us-gaap Depreciation
Depreciation
378000 USD
us-gaap Depreciation
Depreciation
460000 USD
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
508000 USD
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
471000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1412000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1333000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
400000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-4200000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
10789000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
13713000 USD
us-gaap Debt Securities Held To Maturity Credit Loss Expense Reversal
DebtSecuritiesHeldToMaturityCreditLossExpenseReversal
100000 USD
us-gaap Debt Securities Held To Maturity Credit Loss Expense Reversal
DebtSecuritiesHeldToMaturityCreditLossExpenseReversal
0 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
236000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
183000 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
188000 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
egrx Accretion Income
AccretionIncome
56000 USD
egrx Accretion Income
AccretionIncome
0 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1981000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5562000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
219000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1325000 USD
egrx Increase Decreasein Prepaid Expenseand Other Current Assets Total
IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal
1802000 USD
egrx Increase Decreasein Prepaid Expenseand Other Current Assets Total
IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal
-9553000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4868000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8246000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1710000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-8583000 USD
us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
594000 USD
us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
1321000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
19071000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
24110000 USD
us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
0 USD
us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
17500000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
269000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
376000 USD
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
5000000 USD
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5269000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-17876000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1608000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
513000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1551000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1310000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
110000000 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
110000000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
4000000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
2000000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
4297000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
4999000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8240000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-7796000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1562000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
103155000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
109775000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
108717000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
108213000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4300000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
502000 USD
us-gaap Interest Paid Net
InterestPaidNet
625000 USD
us-gaap Interest Paid Net
InterestPaidNet
1458000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
842000 USD
us-gaap Basis Of Accounting
BasisOfAccounting
Basis of Presentation and Other Company Information <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting quarterly information. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. The condensed consolidated balance sheet at December 31, 2020 was derived from audited financial statements, but certain information and footnote disclosures normally included in our annual consolidated financial statements have been condensed or omitted. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the financial information for the interim periods reported have been made. Results of operations for the three and six months ended June 30, 2021 are not necessarily indicative of the results for the year ending December 31, 2021 or any period thereafter. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on March 5, 2021. </span></div><div style="margin-bottom:6pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an integrated pharmaceutical company focused on finding ways to help medicines do more for patients. We and our collaborators have the capabilities to take a molecule from preclinical research through regulatory approval and into the marketplace, including development, manufacturing and commercialization. Our business model applies our scientific expertise, proprietary research-based insights and marketplace proficiency to identify challenging-to-treat diseases of the central nervous system or metabolic critical care therapeutic areas as well as in oncology. By focusing on patients' unmet needs, we strive to provide healthcare professionals with urgently needed treatment solutions that are designed to improve patient care and outcomes and create near- and long-term value for our stakeholders, including patients and healthcare providers and our employees, marketing partners, collaborators and investors. Our science-based business model has a proven track record with U.S. Food and Drug Administration ("FDA") approval and commercial launches of three products: Ryanodex® (dantrolene sodium) ("Ryanodex"), bendamustine ready-to-dilute ("RTD") 500ml solution ("Belrapzo"), and rapidly infused bendamustine RTD ("Bendeka"). We market our products through marketing partners and/or our internal direct sales force. We market Ryanodex and Belrapzo, and Teva Pharmaceutical Industries Ltd. ("Teva") markets Bendeka through its subsidiary Cephalon, Inc. SymBio Pharmaceuticals Limited, or SymBio, markets Treakisym, a lyophilized powder formulation of bendamustine hydrochloride, in Japan. Reflecting further expansion of our oncology portfolio, in February 2020, we received final FDA approval for Pemfexy, a branded alternative to Alimta for metastatic non-squamous non-small cell lung cancer and malignant pleural mesothelioma. We expect to launch Pemfexy in early 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With several pipeline projects underway and the potential for up to five product launches over the next several years, we believe we have many growth opportunities ahead. We believe that each of our pipeline projects currently has the potential to enter the market as a first-in-class, first-to-file, first-to-market or best-in-class product. In particular, we are applying our expertise to conduct novel research regarding the potential for Ryanodex to address conditions including Alzheimer’s disease, traumatic brain injury/concussion, nerve agent exposure and acute radiation syndrome. In addition, our clinical development program includes a strategic partnership with Tyme Technologies, Inc., or Tyme, for Tyme’s product candidate for the treatment of patients with pancreatic or other advanced cancers, SM-88, as well as investigations of compounds such as EA-114 (our fulvestrant product candidate) for patients with HR-positive advanced breast cancer. Other products in development include Vasopressin, our first-to-file Abbreviated New Drug Application, or ANDA, that references Endo International plc’s Vasostrict indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines; and EA-111, a new chemical entity and next-generation ryanodine receptor antagonist, in an intramuscular formulation that that would allow for easier and more rapid administration in emergency situations (military and civilian).</span></div>
egrx Number Of Products Launched
NumberOfProductsLaunched
3 product
CY2021Q2 egrx Number Of Potential Future Product Launches
NumberOfPotentialFutureProductLaunches
5 product
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. Our critical accounting policies are those that are both most important to our financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. We anticipate that the COVID-19 pandemic will continue to disrupt our supply chain and marketing and sales efforts for certain of our products, including Bendeka, although it is not currently expected that any disruption would be significant. As of the date of issuance of these financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, assumptions and judgments or revise the carrying value of our assets or liabilities. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates, and any such differences may be material to our financial statements.</span></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform with the current year presentation, including for amounts related to accounts receivable, net and prepaid expenses and other current assets. None of the amounts pertaining to the reclassifications were significant.</span></div>
CY2021Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
104614000 USD
CY2021Q2 us-gaap Receivables Fair Value Disclosure
ReceivablesFairValueDisclosure
3776000 USD
CY2021Q2 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Asset
EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset
464000 USD
CY2021Q2 us-gaap Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
12600000 USD
CY2021Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
121454000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
79682000 USD
CY2020Q4 us-gaap Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
12200000 USD
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
91882000 USD
CY2021Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2020Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2021Q2 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
400000 USD
CY2020Q2 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
800000 USD
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
700000 USD
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
1900000 USD
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3068064 shares
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3138389 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3035733 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3162966 shares
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
3612000 USD
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-256000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
3191000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3127000 USD
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13108998 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13664951 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13116370 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13666279 shares
CY2021Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
153166 shares
CY2020Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
177550 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2021Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
13262164 shares
CY2020Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
13664951 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
13293920 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
13666279 shares
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.27
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7537000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7268000 USD
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5570000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5191000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1967000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2077000 USD
CY2021Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
188000 USD
CY2020Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
209000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
378000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
460000 USD
CY2021Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
1977000 USD
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3515000 USD
CY2021Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
4578000 USD
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
2589000 USD
CY2021Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1739000 USD
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1971000 USD
CY2021Q2 us-gaap Inventory Net
InventoryNet
8294000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
8075000 USD
CY2021Q2 egrx Prepaid Fda User Fee
PrepaidFDAUserFee
421000 USD
CY2020Q4 egrx Prepaid Fda User Fee
PrepaidFDAUserFee
1262000 USD
CY2021Q2 us-gaap Prepaid Insurance
PrepaidInsurance
743000 USD
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
191000 USD
CY2021Q2 egrx Advances To Commercial Manufacturers
AdvancesToCommercialManufacturers
212000 USD
CY2020Q4 egrx Advances To Commercial Manufacturers
AdvancesToCommercialManufacturers
660000 USD
CY2021Q2 us-gaap Other Assets Current
OtherAssetsCurrent
4458000 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2044000 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5834000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4157000 USD
CY2021Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4339000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4966000 USD
CY2021Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
5910000 USD
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
5996000 USD
CY2021Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
3909000 USD
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
4686000 USD
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2307000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2370000 USD
CY2021Q2 egrx Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
3968000 USD
CY2020Q4 egrx Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
2724000 USD
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1174000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1123000 USD
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3921000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1952000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25528000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23817000 USD
CY2021Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P3Y7M6D
CY2021Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
us-gaap Operating Lease Payments
OperatingLeasePayments
346000 USD
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
1323000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
855000 USD
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y7M6D
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1174000 USD
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3360000 USD
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
4534000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
23100000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
11595000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
11505000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
23100000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
10183000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
12917000 USD
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
706000 USD
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
667000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1412000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1333000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1210000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1369000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1570000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1898000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1520000 USD
CY2021Q2 egrx Finite Lived Intangible Assets Expected Amortization After Year Four
FiniteLivedIntangibleAssetsExpectedAmortizationAfterYearFour
3938000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
11505000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3096161 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
600700 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
38951 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
78478 shares
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3579432 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3331890 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
106000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
94328 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
283998 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3059564 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0051
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0112
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0044
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0165
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5610
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5494
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y8M1D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y10D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4281000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6241000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10789000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13713000 USD
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4281000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6241000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10789000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13713000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5031000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
702000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1423000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1455000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1038000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
413000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
0 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
0 USD
CY2021Q2 us-gaap Long Term Debt
LongTermDebt
30000000 USD
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
4000000 USD
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
26000000 USD
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0 USD
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
0 USD
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
0 USD
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
0 USD
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
0 USD
CY2021Q2 us-gaap Purchase Obligation
PurchaseObligation
48213000 USD
CY2021Q2 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
48213000 USD
CY2021Q2 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
0 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5000000 USD
CY2021Q2 us-gaap Purchase Obligation
PurchaseObligation
48200000 USD
CY2021Q2 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
0 USD
CY2021Q2 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
0 USD
CY2021Q2 us-gaap Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
0 USD
CY2021Q2 us-gaap Purchase Obligation Due In Fifth Year
PurchaseObligationDueInFifthYear
0 USD
CY2021Q2 us-gaap Purchase Obligation Due After Fifth Year
PurchaseObligationDueAfterFifthYear
0 USD
CY2021Q2 us-gaap Contractual Obligation
ContractualObligation
83244000 USD
CY2021Q2 us-gaap Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
52915000 USD
CY2021Q2 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
27423000 USD
CY2021Q2 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
1455000 USD
CY2021Q2 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
1038000 USD
CY2021Q2 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
413000 USD
CY2021Q2 us-gaap Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
0 USD
CY2021Q2 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
0 USD
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
325000 USD
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
351000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
650000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
637000 USD
CY2021Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
8000000 USD
CY2021Q2 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
600000 USD
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
4000000 USD
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
26000000 USD
CY2021Q2 us-gaap Long Term Debt
LongTermDebt
30000000 USD
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1936000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5629000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3697000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3697000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5492000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5492000 USD
CY2021Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.35
CY2020Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
1.05
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.54
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.54
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
2.32
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
2.32
egrx Number Of Tax Jurisdictions Currently Auditing The Company
NumberOfTaxJurisdictionsCurrentlyAuditingTheCompany
3 jurisdiction
CY2021Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD

Files In Submission

Name View Source Status
0000827871-21-000022-index-headers.html Edgar Link pending
0000827871-21-000022-index.html Edgar Link pending
0000827871-21-000022.txt Edgar Link pending
0000827871-21-000022-xbrl.zip Edgar Link pending
egrx-20210630.htm Edgar Link pending
egrx-20210630.xsd Edgar Link pending
egrx-20210630_cal.xml Edgar Link unprocessable
egrx-20210630_def.xml Edgar Link unprocessable
egrx-20210630_htm.xml Edgar Link completed
egrx-20210630_lab.xml Edgar Link unprocessable
egrx-20210630_pre.xml Edgar Link unprocessable
exhibit311q22021.htm Edgar Link pending
exhibit312q22021.htm Edgar Link pending
exhibit321q22021.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending